LEXX
NASDAQ · Pharmaceuticals
Lexaria Bioscience Corp
$5.40
+0.06 (+1.12%)
Financial Highlights (FY 2026)
Revenue
63.2K
Net Income
-1,066,487
Gross Margin
99.6%
Profit Margin
-1,686.0%
Rev Growth
+39.5%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 99.6% | 99.6% | 42.1% | 42.1% |
| Operating Margin | -1,687.4% | -1,518.6% | 21.0% | 24.3% |
| Profit Margin | -1,686.0% | -1,601.7% | 20.1% | 23.6% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 63.2K | 45.3K | 9.47M | 8.19M |
| Gross Profit | 63.0K | 45.1K | 3.98M | 3.44M |
| Operating Income | -1,066,715 | -688,153 | 1.98M | 1.99M |
| Net Income | -1,066,487 | -688,006 | 1.90M | 1.93M |
| Gross Margin | 99.6% | 99.6% | 42.1% | 42.1% |
| Operating Margin | -1,687.4% | -1,518.6% | 21.0% | 24.3% |
| Profit Margin | -1,686.0% | -1,601.7% | 20.1% | 23.6% |
| Rev Growth | +39.5% | +39.5% | +1.1% | -8.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 4.50M | 4.46M |
| Total Equity | — | — | 6.12M | 5.88M |
| D/E Ratio | — | — | 0.74 | 0.76 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -1,059,391 | -721,397 | 3.60M | 2.84M |
| Free Cash Flow | — | — | 1.11M | 1.29M |